Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
Phase 2
12
about 31 years
2–25
1 site in DC
What this study is about
This trial is testing if daratumumab, given before a bone marrow transplant from an identical sibling donor with alemtuzumab, low dose total body irradiation, and sirolimus, can prevent red blood cell problems in people with anti-donor antibodies. The goal is to achieve similar survival rates as those who have transplants without these antibodies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Total Body Irradiation
- 2.Take Alemtuzumab
- 3.Take Daratumumab
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
alemtuzumab, daratumumab, sirolimus
injection (Injection), infusion, injection, intravenous
Primary: To determine the event-free survival of children and adolescents with SCD undergoing nonmyeloablative HCT who received 4 doses of pre-HCT daratumumab for donor-directed red blood cell antibodies.
Secondary: To characterize the safety of adding pre-HCT daratumumab to the conditioning regimen, as defined by adverse events grade 3 or greater.
radiation